Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ANIX 
Anixa Biosciences Inc (ANIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/25/2025: ANIX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -55.16% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/25/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 96.30M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 93500 | Beta 0.86 | 52 Weeks Range 2.07 - 4.20 | Updated Date 03/31/2025 |
52 Weeks Range 2.07 - 4.20 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date 2025-03-21 | When After Market | Estimate -0.1 | Actual -0.1 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -38.42% | Return on Equity (TTM) -62.61% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 78599680 | Price to Sales(TTM) 481.54 |
Enterprise Value 78599680 | Price to Sales(TTM) 481.54 | ||
Enterprise Value to Revenue 368.98 | Enterprise Value to EBITDA -8.76 | Shares Outstanding 32196900 | Shares Floating 30491432 |
Shares Outstanding 32196900 | Shares Floating 30491432 | ||
Percent Insiders 5.29 | Percent Institutions 18.3 |
Analyst Ratings
Rating 4.5 | Target Price 8.5 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Anixa Biosciences Inc
Company Overview
History and Background
Anixa Biosciences Inc. (formerly ITUS Corporation) was founded in 2011. It is a biotechnology company focused on developing therapies and diagnostics for cancer and infectious diseases. Significant milestones include licensing agreements for its technologies and advancements in its CAR-T and vaccine programs.
Core Business Areas
- Cancer Immunotherapy: Focuses on developing novel CAR-T therapies targeting solid tumors, a significant unmet medical need. Their CAR-T technology is being designed to be non-toxic to normal tissues.
- Cancer Diagnostics: Developing a diagnostic technology designed to predict the likelihood of developing cancer years in advance. Focus is on breast and ovarian cancer in women.
- Infectious Disease: Developing therapeutics and preventative treatments for infectious diseases. Currently in early-stage development.
Leadership and Structure
The leadership team includes Dr. Amit Kumar (President & CEO) and other experienced professionals in biotechnology and finance. The company has a Board of Directors that oversees the strategic direction of the company.
Top Products and Market Share
Key Offerings
- CAR-T Therapy Program: Anixa is developing CAR-T therapy designed to be non-toxic and effective against solid tumors. This is still in pre-clinical to early clinical stage. Competitors include larger pharmaceutical companies developing similar CAR-T therapies such as Novartis (NVS), Gilead Sciences (GILD), and Bristol Myers Squibb (BMY), with market share difficult to define at this pre-commercialization stage. The market for solid tumor CAR-T is very large, but largely unaddressed.
- Ccheku2122 diagnostic technology: A diagnostic test designed to predict the likelihood of developing cancer in advance, focusing on breast and ovarian cancer. This test is in development. Competitors include Exact Sciences (EXAS) and Guardant Health (GH), but Anixa aims to provide a test with earlier detection capabilities. Market share is currently zero.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and rapidly evolving, with significant investments in research and development. The immunotherapy and diagnostics segments are experiencing strong growth driven by increasing cancer incidence and demand for personalized medicine.
Positioning
Anixa Biosciences is positioned as an innovative biotechnology company focusing on addressing unmet needs in cancer treatment and prevention. Its competitive advantage lies in its novel CAR-T technology and early cancer detection diagnostic.
Total Addressable Market (TAM)
The total addressable market for cancer immunotherapy and diagnostics is estimated to be in the billions of dollars. Anixa's positioning allows it to potentially capture a significant share of these markets if its products are successful.
Upturn SWOT Analysis
Strengths
- Innovative CAR-T technology targeting solid tumors
- Early-stage cancer diagnostic technology
- Experienced leadership team
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources compared to larger competitors
- Early stage of product development
- Dependence on licensing agreements and partnerships
- Unproven clinical trial data
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of product pipeline
- Positive clinical trial results
- Increasing demand for personalized medicine
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles and approval delays
- Clinical trial failures
- Patent challenges
Competitors and Market Share
Key Competitors
- NVS
- GILD
- BMY
- EXAS
- GH
Competitive Landscape
Anixa faces significant competition from established pharmaceutical and diagnostics companies with greater resources and established market presence. Anixa's competitive advantage lies in its novel technologies and focus on unmet medical needs.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by research and development progress and securing funding. The company has not yet generated significant revenue from product sales.
Future Projections: Future growth is dependent on clinical trial success and regulatory approvals. Analyst estimates suggest potential for significant revenue growth if its products are successful.
Recent Initiatives: Recent initiatives include advancing its CAR-T program into clinical trials and expanding its diagnostic platform.
Summary
Anixa Biosciences is a high-risk, high-reward biotechnology company with promising technologies in CAR-T therapy and cancer diagnostics. Its success hinges on positive clinical trial results and securing partnerships with larger companies. It needs to secure additional funding to keep the operation running while managing the competitive challenges from well established pharma companies.
Similar Companies
- NVS
- GILD
- BMY
- EXAS
- GH
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Company Website
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. The analysis is based on publicly available data and is subject to change without notice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Anixa Biosciences Inc
Exchange NASDAQ | Headquaters San Jose, CA, United States | ||
IPO Launch date 1987-01-01 | CEO, Chairman & Co-Chair of CBAB Dr. Amit Kumar Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.anixa.com |
Full time employees 5 | Website https://www.anixa.com | ||
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company's vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the development of a vaccine against ovarian cancer, as well as a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.